Global Neuropathic Pain Treatment Market

Global Neuropathic Pain Treatment Market

Analysis by Drug Class (Gabapentinoids, SNRIs and TCAs, Topical Agents, Opioids and Tramadol, Sodium-Channel Anticonvulsants, Novel Non-Opioid Agents, Others), Indication (Painful Diabetic Peripheral Neuropathy, Radiculopathy, Postherpetic Neuralgia, Chemotherapy-Induced Neuropathy, Post-Surgical and Post-Traumatic, Central Neuropathic Pain, Trigeminal Neuralgia, Others), Route of Administration, Distribution Channel and Region

Report ID: HP04 | Format: PDF, Excel | Publish Date: November 2026 | Pages: 120

1. Executive Summary
•    1.1 Key Findings
•    1.2 Market Snapshot: Value, Treated Patients and Revenue per Patient, 2024, 2025 and 2030
•    1.3 Analyst Viewpoint
2. Research Methodology
•    2.1 Research Scope and Market Definition
•    2.2 Data Sources: Primary and Secondary Research
•    2.3 Market Sizing Approach: Patient-Based and Sales-Based Models
•    2.4 Patient Funnel Construction and Assumptions
•    2.5 Pricing and Revenue per Patient Estimation
•    2.6 Pipeline Tracking and Probability-of-Success Adjustments
•    2.7 Forecasting Assumptions and Data Triangulation
•    2.8 Abbreviations
3. Global Neuropathic Pain Treatment Market Outlook
•    3.1 Market Value, 2020–2030 (US$ Billion)
•    3.2 Year-on-Year Growth Momentum, 2021–2030
•    3.3 Treated Patient Population, 2020–2030
•    3.4 Revenue per Treated Patient, 2020–2030
4. Epidemiology and Patient Funnel
•    4.1 Prevalence of Neuropathic Pain by Region
•    4.2 Diagnosis Rates
•    4.3 Treatment Rates and Guideline Adherence
•    4.4 Treatment Response and Unmet Need
5. Market Dynamics
•    5.1 Drivers
•    5.1.1 Non-Opioid Therapeutic Innovation
•    5.1.2 Rising Diabetes and Cancer Survivorship
•    5.1.3 Ageing Populations and Shingles Burden
•    5.2 Restraints
•    5.2.1 Generic Erosion of Established Therapies
•    5.2.2 Step Therapy and Reimbursement Barriers
•    5.3 Opportunities
•    5.3.1 Underserved Indications (CIPN, Central Pain, Trigeminal Neuralgia)
•    5.3.2 Topical and Localized Therapies
•    5.3.3 Emerging-Market Diagnosis Expansion
•    5.4 Challenges
•    5.4.1 High Placebo Response and Clinical Attrition
•    5.4.2 Opioid Prescribing Restrictions
6. Global Market Analysis by Drug Class
•    6.1 Gabapentinoids
•    6.2 SNRIs and TCAs
•    6.3 Topical Agents
•    6.4 Opioids and Tramadol
•    6.5 Sodium-Channel Anticonvulsants
•    6.6 Novel Non-Opioid Agents
•    6.7 Others
7. Global Market Analysis by Indication
•    7.1 Painful Diabetic Peripheral Neuropathy
•    7.2 Painful Radiculopathy and Sciatica
•    7.3 Postherpetic Neuralgia
•    7.4 Chemotherapy-Induced Peripheral Neuropathy
•    7.5 Post-Surgical and Post-Traumatic Neuropathic Pain
•    7.6 Central Neuropathic Pain
•    7.7 Trigeminal Neuralgia
•    7.8 Others
8. Global Market Analysis by Route of Administration
•    8.1 Oral
•    8.2 Topical
•    8.3 Injectable
9. Global Market Analysis by Distribution Channel
•    9.1 Hospital Pharmacies
•    9.2 Retail Pharmacies
•    9.3 Online Pharmacies
10. Generic vs Branded Market Analysis
•    10.1 Prescription Share
•    10.2 Value Share
•    10.3 Loss-of-Exclusivity Timeline
11. Regional Analysis (Value, Treated Patients, Revenue per Patient, 2020–2030)
•    11.1 North America (U.S., Canada, Mexico)
•    11.2 Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
•    11.3 Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, Rest of Asia Pacific)
•    11.4 Latin America (Brazil, Argentina, Rest of Latin America)
•    11.5 Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa)
12. Clinical Pipeline Analysis
•    12.1 Pipeline by Phase
•    12.2 Pipeline by Mechanism of Action
•    12.3 Key Late-Stage Programmes and Expected Readouts
•    12.4 Launch Timeline and Peak Sales Scenarios
13. Regulatory and Reimbursement Landscape
•    13.1 United States (FDA, Payer Policies)
•    13.2 European Union (EMA, HTA)
•    13.3 Japan and China
•    13.4 Opioid Prescribing Regulations
14. Competitive Landscape
•    14.1 Market Structure and Concentration
•    14.2 Recent Mergers, Licensing and Restructuring
•    14.3 Epignosis Insights Competitive Assessment Framework (EICAF)
•    14.4 EICAF Scoring Method and Company Rankings
15. Company Profiles
•    15.1 Viatris
•    15.2 Eli Lilly and Company
•    15.3 Grünenthal (incl. Averitas Pharma)
•    15.4 Daiichi Sankyo
•    15.5 Vertex Pharmaceuticals
•    15.6 Lexicon Pharmaceuticals
•    15.7 Keenova Therapeutics (formerly Mallinckrodt and Endo)
•    15.8 Teva Pharmaceuticals
•    15.9 Sun Pharmaceutical Industries
•    15.10 Zydus Lifesciences
•    15.11 Lupin
•    15.12 Dr. Reddy's Laboratories
•    15.13 Cipla
•    15.14 Aurobindo Pharma
•    Each profile: Company Overview, Neuropathic Pain Portfolio, Pipeline, Financial Snapshot, Recent Developments
16. Strategic Recommendations
•    16.1 For Innovator Companies
•    16.2 For Generic Manufacturers
•    16.3 For Payers and Healthcare Systems
•    16.4 For Investors
17. Appendix
•    17.1 List of Tables
•    17.2 List of Figures
•    17.3 Disclaimer

Frequently Asked Questions

What is the global neuropathic pain treatment market size in 2025?
The global neuropathic pain treatment market is valued at approximately US$6.30 billion in 2025, according to Epignosis Insights estimates.
What is the expected market size by 2030?
The market is projected to reach approximately US$8.42 billion by 2030, representing a 5.7% CAGR from 2024 to 2030.
How many patients receive treatment for neuropathic pain?
Epignosis Insights estimates that about 72 million patients received prescription therapy in 2025, rising to around 85.6 million by 2030.
Which region leads the neuropathic pain treatment market?
North America leads with 42.4% of 2025 market value, while Asia Pacific is the fastest growing major region.
Which drug class is growing fastest?
Novel non-opioid agents are forecast to grow from about 1% of market value in 2025 to 13% by 2030.

Small Analyst Support Card

Need Help Choosing the Right Report

Talk to Our Analyst